Imago BioSciences Announces Completion of Enrollment in Phase 2 Clinical Study of Bomedemstat in Essential Thrombocythemia
May 03, 2022 08:00 ET
|
Imago Biosciences, Inc.
Interim Data Update at European Hematology Association (EHA) meeting in June and Results from Completed Phase 2 Study Expected in Second Half of 2022 End-of-Phase 2 Meeting with U.S. Food and...
Imago BioSciences to Host Virtual Investor Event
December 01, 2021 08:00 ET
|
Imago Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Dec. 01, 2021 (GLOBE NEWSWIRE) -- Imago BioSciences, Inc. (“Imago” or the “Company”) (Nasdaq: IMGO), a clinical stage biopharmaceutical company discovering new...
Imago BioSciences to Present at Stifel 2021 Virtual Healthcare Conference
November 11, 2021 16:05 ET
|
Imago Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Imago BioSciences, Inc. (“Imago”) (Nasdaq: IMGO), a clinical stage biopharmaceutical company discovering new medicines for the...
Imago BioSciences Reports Third Quarter 2021 Financial Results and Provides Recent Business Updates
November 10, 2021 16:05 ET
|
Imago Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Imago BioSciences, Inc. (“Imago”) (Nasdaq: IMGO), a clinical-stage biopharmaceutical company discovering new medicines for the...